Table 3 Infectious complications in common variable immunodeficiency
| Â | Mount Sinai 1999 [3] (n = 248) | Mount Sinai 2011 [38] (n = 473) | DEFI 2008 [4] (n = 252) |
|---|---|---|---|
Recurrent (respiratory tract) infections | 98% (243/248) | 94% (445/473) | 91% (230/252) |
Pneumoniaa | 76.6% (190/248) | 40% (187/473) | 58% (147/252) |
Meningitis | <1% (2/248) | NS | 7.9% (20/252) |
Viral hepatitis | 6.5% (16/248) | 3.4% (16/473) | 1.2% (3/252) |
Giardia enteritis | 3.2% (8/248) | 2.3% (11/473) | 13.9% (35/252) |
(Recurrent) Herpes zoster | 3.6% (9/248) | 2.5% (12/473) | 11% (27/252) |
Pneumocystis jiroveci infection | 2.8% (7/248) | 1.3% (6/473) | <1% (2/252) |
Salmonella infection | 1.2% (3/248) | <1% (4/473) | 7.5% (19/252) |
Mycoplasma infection | 2.8% (7/248) | <1% (4/473) | NS |
Candidiasis | 1.2% (3/248) | <1% (3/473) | <1% (2/252) |
Mycobacterial disease | <1% (1/248) | <1% (3/473) | <1% (2/252) |
Papilloma viral infection | NS | <1% (3/473) | <1% (13/252) |